Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates
Jaguar Health, Inc. (NASDAQ:JAGX) announced an investor webcast on May 10, 2022, at 8:30 AM Eastern Time to discuss first-quarter 2022 financial results and corporate updates. The earnings report will be filed on May 10, 2022, on Form 10-Q. Jaguar focuses on developing plant-based, non-opioid medicines for gastrointestinal issues in both humans and animals. The company is known for its drug candidate, crofelemer, which is currently involved in a pivotal Phase 3 clinical trial for diarrhea in cancer patients receiving targeted therapy.
- None.
- None.
Click here to register for webcast
Company plans to file its Earnings Report on May 10, 2022 on Form 10-Q for the quarter ended March 31, 2022
SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Tuesday, March 10, 2022, at 8:30 a.m. Eastern Time to review first-quarter 2022 financials and provide corporate updates.
Participation Instructions for Webcast
When: Tuesday, May 10, 2022, at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals, & Napo Therapeutics
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Animal Health is a tradename of Jaguar Health. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe.
For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar Health's expectation that an investor webcast will take place May 10, 2022. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/700036/Jaguar-Health-to-Host-Investor-Webcast-Tuesday-May-10th-at-830-AM-Eastern-Time-Regarding-Q1-2022-Financials-Corporate-Updates
FAQ
What date is Jaguar Health's earnings report filing scheduled?
When will the investor webcast for Jaguar Health take place?
What is the focus of Jaguar Health's drug development?
What is crofelemer and what trial is it involved in?
What is the purpose of the May 10 webcast by Jaguar Health?
